Psoriasis
Psoriasis is a chronic, noncontagious autoimmune disease that manifests as patches of thick, red, scaly, and often itchy skin, which can vary in severity from localized areas to widespread coverage. The cause is unknown, symptoms fluctuate over time, and skin injuries can trigger the condition, known as the Koebner phenomenon.
Health Outcomes
- Accelerated Immune Response Maturation
- Achieved Inflammation Homeostasis
- Activated Immune Response
- Adjusted Immune Function
- Altered Epithelial Plasma Membrane Properties
- Altered Expression of Immune Products
- Altered Expression of Immune-Related Genes
- Altered Hydrophobicity
- Altered IFN-γ Levels
- Altered NF-kappaB Signaling
- Altered Pro-Inflammatory Cytokine Levels
- Altered Serum Immune Protein Levels
- Altered Systemic Immune Response
- Altered T Cell Migratory Behavior
- Altered T Cell Subsets
- Altered TH1/TH2 Immune Response
- Balanced Treg/Th17 Regulation
- Beneficial Clinical Effects
- Changes in Inflammatory Markers
- Chronic Immune Activation
- Cosmetic Material Identification
- Decreased Naïve CD45RA+ T Helper Cells
- Decreased TNFα Levels
- Elevated Blood Cytokine Levels
- Elevated Ceramide Levels in Skin
- Elevated IL-22 Levels
- Elevated Interleukin-10 Levels
- Elevated Interleukin-12 Levels
- Elevated Interleukin-17 Levels
- Elevated Interleukin-8 Levels
- Elevated Serum TNF-α Levels
- Elevated TNF-α Expression Level
- Enhanced Adjuvanticity
- Enhanced Anti-inflammatory Cytokine Expression During Healing
- Enhanced Anti-inflammatory Cytokine Levels
- Enhanced Anti-inflammatory Properties
- Enhanced Anti-inflammatory Response
- Enhanced Barrier Integrity
- Enhanced Cytokine Response
- Enhanced Delayed-Type Hypersensitivity Response
- Enhanced Dendritic Cell-T Cell Interaction
- Enhanced Epidermal Differentiation
- Enhanced Epithelial Cell Defense Functions
- Enhanced Epithelial Cell Migration
- Enhanced Host Defense Peptides Activation
- Enhanced IL-12 Production
- Enhanced Immune Function Post-Cessation
- Enhanced Immune Modulation
- Enhanced Immune Regulation
- Enhanced Immunity
- Enhanced Immunogenicity
- Enhanced Immunomodulatory Function
- Enhanced Immunoregulatory Function
- Enhanced Immunoregulatory Molecule Activity
- Enhanced Inflammation Resolution
- Enhanced Inflammatory Response
- Enhanced Innate Immune Response
- Enhanced Interleukin-10 Production
- Enhanced Leukocyte Recruitment
- Enhanced Lymphocyte Proliferation
- Enhanced Membrane Barrier Integrity
- Enhanced Phagocytic Function
- Enhanced Phenoloxidase Activity
- Enhanced Phototherapy Outcome
- Enhanced Pro-Inflammatory Cytokine Response
- Enhanced Production of Natural Moisturizing Factor
- Enhanced Regulatory T Cell Development
- Enhanced Regulatory T Cell Function
- Enhanced Safety in Topical Application
- Enhanced Skin Gloss
- Enhanced Skin Mucosal Immune Parameters
- Enhanced Skin Mucus Protease Activity
- Enhanced T- and B-Lymphocyte Proliferation
- Enhanced Treg Cell Differentiation
- Enhanced Type 1 Immune Response
- Enhanced β-Defensin 3 Activity
- Good Tolerability
- High Treatment Acceptability
- Improved Adhesion Characteristics
- Improved Antigen Presentation
- Improved Antioxidant and Anti-Inflammatory Response
- Improved Barrier Integrity
- Improved Cell Adhesion
- Improved Clinical Disease Activity
- Improved Consumer Acceptability
- Improved Cytokine Levels
- Improved Cytokine Production
- Improved Dendritic Cell Activation
- Improved Dermatology Life Quality Index
- Improved Epidermal Lipid Barrier Function
- Improved Epidermal Moisturization
- Improved Epithelial Integrity
- Improved Epithelial Protection
- Improved Filaggrin Production
- Improved Free Radical Scavenging Activity
- Improved Granulocyte Oxidative Burst
- Improved Histopathological Protection
- Improved Humoral Immunity
- Improved IL-10/TNF-α Ratio
- Improved Immune Balance
- Improved Immune Regulation
- Improved Immune Response in Individuals with Poor Pretreatment
- Improved Immune System Function via JAK-STAT Pathway Activation
- Improved Immune System Maturation
- Improved Immune-Related Symptoms
- Improved Immunoinflammatory Markers
- Improved Immunologic Barrier Function
- Improved Immunological Biomarkers
- Improved Immunomodulation
- Improved Inflammation Homeostasis
- Improved Inflammation Levels
- Improved Inflammatory Biomarkers
- Improved Inflammatory Marker Profile
- Improved Inflammatory Profile
- Improved Inflammatory Regulation
- Improved Inflammatory Response
- Improved Inflammatory Status
- Improved Keratinocyte Differentiation
- Improved Lesion Regression
- Improved Lipid Barrier Function
- Improved Monocyte Activation
- Improved Overall Patient Outcomes
- Improved Peripheral Blood Lymphocyte Proliferation
- Improved Protein Kinase C Activity
- Improved Psoriasis Severity
- Improved Regulatory T Cell Function
- Improved Skin Barrier Function
- Improved Skin Cell Proliferation
- Improved Skin Condition
- Improved Skin Condition Score
- Improved Skin Disease Severity
- Improved Skin Elasticity
- Improved Skin Health
- Improved Skin Immunity
- Improved Skin Moisture Retention
- Improved Skin Mucus Lysozyme Activity
- Improved Skin Recovery
- Improved Skin Responses
- Improved Skin Satisfaction
- Improved Skin Symptoms
- Improved Symptom Relief
- Improved Systemic Immune Response
- Improved T-Cell Cytokine Production
- Improved Tissue Pathology
- Improved Treatment Efficacy
- Improved Treg/Th-17 Balance
- Improved Viability of Keratinocytes
- Increased Activation of Regulatory T Cells
- Increased Adhesion to Epithelia
- Increased Angiogenesis
- Increased Anti-Inflammatory Cytokine IL-10
- Increased Anti-Inflammatory Cytokine Levels
- Increased Anti-Inflammatory Levels
- Increased Anti-inflammatory Cytokines
- Increased Anti-inflammatory Phenotype in Dendritic Cells
- Increased Anti-inflammatory to Pro-inflammatory Cytokine Ratio
- Increased Antibody Production
- Increased Antigen-Presenting Cell Activation
- Increased Antioxidant Activity
- Increased Barrier-Preserving Protein Levels
- Increased Basal Layer Epithelial Cellularity
- Increased Beneficial Gut Bacteria
- Increased C-Reactive Protein Level
- Increased CD4-Positive T-Lymphocytes
- Increased CD8 Percentage
- Increased Circulating 25-Hydroxyvitamin D Levels
- Increased Circulating Immune Cell Count
- Increased Complement C3 Level
- Increased Cytokine Production
- Increased Cytokine Production in Peripheral Blood Mononuclear Cells
- Increased Cytokine Response
- Increased Cytokine Secretion
- Increased Dendritic Cell Activation
- Increased EGF Level
- Increased Epithelial Proliferation
- Increased Expression of Antimicrobial Peptide Genes
- Increased Expression of Beta-Defensin 3
- Increased Expression of Human Beta Defensin-2
- Increased Expressions of β-Defensins
- Increased Foxp3 Protein Levels
- Increased Generation of T Regulatory Cells
- Increased Helper T Cell Activation
- Increased Host Defense Peptide Levels
- Increased IFN-γ Levels
- Increased IFN-γ to IL-4 Ratio
- Increased IL-10 Levels
- Increased IL-10 Production
- Increased IL-12 Production in Splenocytes
- Increased IL-17 Levels
- Increased IL-2 Secretion
- Increased Immune Activation without Cytotoxicity
- Increased Immune Marker Activation
- Increased Immune Marker Levels
- Increased Immune Response
- Increased Immune System Activation
- Increased Immunosuppressive Cytokine Production
- Increased Inflammatory Cytokines
- Increased Inflammatory Mediator Production
- Increased Inflammatory Response
- Increased Interferon-Gamma Levels
- Increased Interleukin 12 Secretion from Dendritic Cells
- Increased Interleukin-1 Beta Production
- Increased Interleukin-10 Levels
- Increased Interleukin-12p40 Production
- Increased LL-37 Level
- Increased LL-37 Levels
- Increased Levels of Actinobacteria
- Increased Lymphocyte Proliferation
- Increased Minimal Erythema Dose
- Increased Peripheral Blood B Cell Frequency
- Increased Pro-inflammatory Cytokine Production
- Increased Pro-inflammatory Cytokine Release
- Increased Pro-inflammatory Cytokine TNFα Levels
- Increased Pro-inflammatory Cytokines in Early Healing Phase
- Increased Production of Antimicrobial Peptides
- Increased Proportion of Activated T Lymphocytes
- Increased Proportion of T Lymphocytes
- Increased Regulatory T Cell Count
- Increased Regulatory T Cell Expansion
- Increased Regulatory T Cell Response
- Increased Serum IL-10 Levels
- Increased Serum Metabolites to Combat Inflammation
- Increased Serum Tumor Necrosis Factor-α Levels
- Increased Skin Mucus IgG Levels
- Increased Skin Thickness
- Increased Surface Activity
- Increased T Cell Activation
- Increased T-helper Type 1 Cytokine Concentrations
- Increased TNF-alpha Levels in Macrophages
- Increased TNF-α Production
- Increased Th1-Associated Cytokine Release
- Increased Th1-Dependent Contact Sensitivity
- Increased Th17 Polarization
- Increased Tolerance to Inflammatory Stimuli
- Increased Tumor Necrosis Factor-Alpha Levels
- Increased Tumor Necrosis Factor-Alpha Production by Dendritic Cells
- Induced Immunomodulatory Effects
- Induced Th1 Cytokines
- Inflammatory Disease Protection
- Influenced Systemic Immune Response
- Inhibited Autoimmune Activation
- Maintained Barrier Function
- Maintained Epithelial Barrier Integrity
- Maintained Epithelium Structure
- Maintained Morphological Integrity
- Maintained Remission of Skin Symptoms
- Matured Antigen-Presenting Cells
- Modulated Cytokine Production
- Modulated Dendritic Cell Function
- Modulated Eicosanoid Levels
- Modulated Host Response
- Modulated Humoral Inflammation
- Modulated Immune System
- Modulated Immunoinflammatory Parameters
- Modulated Immunologic Response
- Modulated Immunological Profile
- Modulated Inflammation and Coagulation Interaction
- Modulated Inflammatory Cytokine Levels
- Modulated Inflammatory Response
- Modulated Innate Immune Response
- Modulated Lymphocyte Populations
- Modulated Peripheral Immune Response
- Modulated Systemic Immune Response
- Modulated T Cell Response
- No Adverse Effects on Body Weight or Food Intake
- No Change in C-Reactive Protein
- No Change in Oxidative Stress Markers
- No Change in Skin Mucus Protease Activity
- No Meaningful Change in IL-10
- No Meaningful Change in IL-8
- No Reduction in Atopic Dermatitis Severity
- No Serious Treatment-Related Adverse Events
- No Significant Change in Blood Indices
- No Significant Change in Tumor Necrosis Factor Alpha Levels
- No Significant Effect on C-Reactive Protein Levels
- No Significant Impact on Bacterial Community Composition or Diversity
- No Significant Reduction in Atopic Dermatitis Severity
- Potential Skin Effect
- Prevention and Treatment of Inflammatory Diseases
- Protected Epithelial Cells Under Inflammatory Conditions
- Protection Against Oxidative Stress
- Rebalanced Th1/Th2/Th17 Cell Ratios
- Reduced Abundance of Pro-inflammatory Bacteria
- Reduced Aggravation of Chronic Inflammation
- Reduced Apoptotic Shedding of Epithelial Cells
- Reduced Catalase Activity
- Reduced Ceramide Production
- Reduced Chemokine Levels
- Reduced Cytokine Response
- Reduced Dermal Irritation
- Reduced Disease Activity
- Reduced Epithelial Barrier Disruption
- Reduced Erythema Intensity
- Reduced Expression of CTACK
- Reduced Expression of Inflammation-Related Genes
- Reduced Expression of Proinflammatory Mediators
- Reduced Histological Damage Scores
- Reduced IL-17 Production in Splenocytes
- Reduced IL-1β Levels
- Reduced IL-6 Production
- Reduced IL-8 Production
- Reduced IL-8 Secretion
- Reduced IL-9 Levels
- Reduced IkappaB Alpha Degradation
- Reduced Immune Activation
- Reduced Immunoinflammatory Markers
- Reduced Inflammation
- Reduced Inflammation Levels
- Reduced Inflammation Markers
- Reduced Inflammation in Dendritic Cells
- Reduced Inflammatory Activities
- Reduced Inflammatory Biomarker Level
- Reduced Inflammatory Cell Activity
- Reduced Inflammatory Cytokine Secretion from Activated T Cells
- Reduced Inflammatory Cytokines (TNF-α, IFN-γ, IL-6)
- Reduced Inflammatory Diseases
- Reduced Inflammatory Effects
- Reduced Inflammatory Factor Production
- Reduced Inflammatory Immune Mediators
- Reduced Inflammatory Infiltrate
- Reduced Inflammatory Injury
- Reduced Inflammatory Marker IL-1β
- Reduced Inflammatory Markers
- Reduced Inflammatory Mediators
- Reduced Inflammatory Molecules
- Reduced Inflammatory Parameters
- Reduced Inflammatory Pathway Activity
- Reduced Inflammatory Pathways
- Reduced Inflammatory Processes
- Reduced Inflammatory Protein Activation
- Reduced Inflammatory Response
- Reduced Inflammatory Response to Inflammatory Stimulus
- Reduced Inflammatory Status
- Reduced Inflammatory Stimulators
- Reduced Inflammatory Tone
- Reduced Intercellular Adhesion Molecule-1
- Reduced Interleukin Level
- Reduced Interleukin-1β Concentration
- Reduced Interleukin-22 Level
- Reduced Interleukin-8 Secretion
- Reduced Investigator Global Assessment
- Reduced LPS-Induced Inflammation
- Reduced Lesion Size
- Reduced Levels of Anti-Inflammatory Cytokines
- Reduced Levels of Interleukin-17
- Reduced Local Inflammation
- Reduced MAPK Activation
- Reduced Monocyte Chemoattractant Protein-1 Level
- Reduced Neutrophil Extracellular Trap Formation
- Reduced Neutrophil Infiltration
- Reduced Neutrophil Recruitment
- Reduced PMN Cell Migration Towards Inflammatory Mediators
- Reduced Pathological Symptoms
- Reduced Peripheral Inflammation
- Reduced Plasma Tumor Necrosis Factor-α Levels
- Reduced Pro-Inflammatory Cells
- Reduced Pro-Inflammatory Cytokine Synthesis
- Reduced Pro-Inflammatory Cytokines
- Reduced Pro-Inflammatory Factor TNF-α
- Reduced Pro-Inflammatory Immune Activity
- Reduced Pro-Inflammatory Mediator Production
- Reduced Pro-inflammatory Biomarker Level
- Reduced Pro-inflammatory Cytokine Interleukin-8 Levels
- Reduced Pro-inflammatory Cytokine Levels
- Reduced Pro-inflammatory Cytokine Release
- Reduced Pro-inflammatory Effect
- Reduced Pro-inflammatory Gene Transcription
- Reduced Pro-inflammatory Immune Responses
- Reduced Pro-inflammatory Mediator Levels
- Reduced Proinflammatory Cytokine Production
- Reduced Proinflammatory Cytokine Secretion
- Reduced Proinflammatory Cytokines Gene Transcription
- Reduced Proinflammatory Cytokines in Middle-aged Adults
- Reduced Proinflammatory Factor Levels
- Reduced Proinflammatory Factors
- Reduced Proinflammatory Mediators
- Reduced Proinflammatory Profile
- Reduced Proinflammatory/Anti-inflammatory Cytokine Ratios
- Reduced Pruritus
- Reduced Psoriasis Area and Severity Index
- Reduced Psoriasis Inflammation
- Reduced Psoriasis Symptoms
- Reduced Release of Inflammatory Mediators (TNF-α, IL-6, IL-1β, IL-10)
- Reduced Risk of Chronic Inflammatory Diseases
- Reduced Scratching Frequency
- Reduced Serum CTACK Levels
- Reduced Serum Cytokine Levels
- Reduced Serum Inflammatory Cytokines
- Reduced Serum Inflammatory Factors
- Reduced Serum TNF-α Levels
- Reduced Serum Tumor Necrosis Factor-α
- Reduced Skin Dryness Symptoms
- Reduced Skin Flakiness
- Reduced Skin Inflammation
- Reduced Skin Redness
- Reduced Skin and Eye Irritation
- Reduced Susceptibility to Inflammatory Exposure
- Reduced Systemic Inflammatory Response
- Reduced TH17 Response
- Reduced TNF Production
- Reduced TNF-alpha Level
- Reduced TNF-α Concentration
- Reduced TNF-α Levels
- Reduced TNF-α Secretion
- Reduced TNF-α Signaling
- Reduced Th1/Th2 Ratio
- Reduced Topical Corticosteroid Use
- Reduced Topical Steroid Usage
- Reduced Tumor Necrosis Factor Alpha
- Reduced Tumor Necrosis Factor Alpha Production
- Reduced Tumor Necrosis Factor-alpha Level
- Reduced Tumor Necrosis Factor-α (TNF-α)
- Reduced Tumor Necrosis Factor-α Levels
- Regulated Immune Cell Proliferation
- Regulated Inflammatory Cytokines
- Regulated Inflammatory Markers
- Regulated Inflammatory Process
- Regulated Inflammatory Responses
- Regulated Systemic Immune Response Imbalance
- Resolved Lesion
- Restored Barrier Function
- Restored Th1/Th2 Cytokine Balance
- Restored Treg Cell Population in MLNs
- Safety Comparable to Control
- Stabilized Skin Microbiome
- Stable Inflammatory Responses
- Stimulation of Immune Cells
- Suppressed Inflammatory Chemokine Secretion
- Suppressed TNF-α Induced Genes
- Sustained Anti-Inflammatory Gene Transcription
- Th1 Polarized Immune Response Through Activation of moDCs
- Unchanged Heat Shock Protein Levels
- Unchanged Inflammatory Response
- Upregulated Macrophage Inhibitory Factor
- Worsened Autoimmune Manifestations